reek

　 　 　 　

WordNet

1. give off smoke, fumes, warm vapour, steam, etc.; "Marshes reeking in the sun"
2. be wet with sweat or blood, as of ones face (同)fume
3. smell badly and offensively; "The building reeks of smoke" (同)stink
4. of or relating to or characteristic of Greece or the Greeks or the Greek language; "Greek mythology"; "a Grecian robe" (同)Grecian, Hellenic
5. a native or inhabitant of Greece (同)Hellene
6. the Hellenic branch of the Indo-European family of languages (同)Hellenic, Hellenic language
7. erect or spreading perennial of the eastern United States (同)Polemonium reptans
8. a member of the Greek Orthodox Church
9. the syllable naming the second (supertonic) note of any major scale in solmization (同)ray
10. giving off a strong unpleasant smell
11. wet with secreted or exuded moisture such as sweat or tears; "wiped his reeking neck" (同)watery

PrepTutorEJDIC

1. 悪臭 / (…の)悪臭を放つ,くさいにおいがする《+『of』+『名』》 / (汗・血などに)まみれる《+『with』+『名』》
2. 〈C〉『ギリシア人』 / 〈U〉『ギリシア語』 / 〈U〉訳の分からない言葉 / ギリシアの;ギリシア人の;ギリシア語の
3. レ(全音階の第2音)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/12/07 00:21:54」(JST)

wiki en

[Wiki en表示]

Reek may refer to:

• Reek (compound), a volatilized chemical compound that humans or other animals perceive by the sense of olfaction
• Reek (creature), a fictional creature in the Star Wars universe
• Reek (Netherlands)
• The Reek, a mountain in the west of Ireland
• Reek da Villian (21st century), American rapper

People with the surname

• Nikolai Reek (1890-1942), Estonian military commander

• Michael Reek Mercer (b. 1983), Domino Records

English Journal

• Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases.

• van den Reek JM, van Lümig PP, Janssen M, Schers HJ, Hendriks JC, van de Kerkhof PC, Seyger MM, de Jong EM.Author information Department of Dermatology, Radboud University Nijmegen Medical Centre, NijmegenDepartment of Rheumatology, Rijnstate Hospital, ArnhemDepartment of Primary and Community Care, Radboud University Nijmegen Medical CentreDepartment of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.AbstractBackground  Auto-immune inflammatory rheumatic diseases (AIRD) are often successfully treated with the immunosuppressant azathioprine for years. Treatment with azathioprine has been proven to increase the risk of non-melanoma skin cancer (NMSC) in transplant patients and possibly in patients with inflammatory bowel disease as well. Little is known about the risk of NMSC in AIRD patients treated with azathioprine. Objectives  The aim of this study is to determine the incidence of NMSC in patients with AIRD treated with azathioprine for at least 1 year, as compared with the general Dutch population. Methods  Data were extracted from a historical cohort of patients with AIRD in a tertiary care centre. We compared the incidence to an age-matched control population and analysed risk factors for NMSC with univariate logistic regression. Results  Fifty-nine patients were analysed. No patients were diagnosed with basal cell carcinoma and four patients with a single squamous cell carcinoma (SCC). Patients with SCC had a higher cumulative dose of azathioprine (≥500 g: OR 30.0 [95% CI 2.6-345.1]) and longer treatment duration (≥11 years: OR 13.5 [95% CI 1.3-143.6]). The risk of SCC compared with the general Dutch population was increased (standardized incidence ratio of 16.0 [95% CI 0.3-31.7]). Conclusions  In this cohort of patients with AIRD treated with azathioprine for at least 1 year, the risk of SCC was increased, as compared with the general population. An individual cumulative dose of at least 500 g azathioprine and a treatment duration of at least 11 years were quantified as risk factors.
• Journal of the European Academy of Dermatology and Venereology : JEADV.J Eur Acad Dermatol Venereol.2014 Jan;28(1):27-33. doi: 10.1111/jdv.12041. Epub 2012 Dec 6.
• Background  Auto-immune inflammatory rheumatic diseases (AIRD) are often successfully treated with the immunosuppressant azathioprine for years. Treatment with azathioprine has been proven to increase the risk of non-melanoma skin cancer (NMSC) in transplant patients and possibly in patients with
• PMID 23216663

• Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis: One-Year Follow-up.

• Menting SP1, van Lümig PP2, de Vries AC1, van den Reek JM2, van der Kleij D3, de Jong EM2, Spuls PI1, Lecluse LL1.Author information 1Department of Dermatology, Academic Medical Center, Amsterdam, the Netherlands.2Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.3Laboratory for Monoclonal Therapeutics, Sanquin Diagnostic Services, Amsterdam, the Netherlands.AbstractIMPORTANCE In a previously reported cohort of 29 patients with plaque-type psoriasis followed up for 24 weeks, clinically relevant antidrug antibody (ADA) to adalimumab was frequently found. Long-term data were lacking. We now present the extension of this study: 80 patients followed up for 1 year. OBJECTIVES To assess the extent of ADA and its clinical consequences after 24 weeks of adalimumab treatment for psoriasis in a cohort of 80 patients. DESIGN, SETTING, AND PARTICIPANTS A multicenter cohort study, performed in the outpatient dermatology clinic of 2 academic hospitals, included 80 sequential patients receiving adalimumab therapy for plaque-type psoriasis and had a follow-up of 1 year. Outcome assessors were not aware of the presence of antibodies to adalimumab or the adalimumab serum concentration when assessing patients' Psoriasis Area and Severity Index (PASI), and personnel analyzing serum samples were blinded to patients' PASI. INTERVENTIONS For 80 patients treated with adalimumab for psoriasis, disease severity (PASI) was assessed, blood samples were collected, and adalimumab and ADA concentrations was determined at baseline and at weeks 12, 24, and 52. MAIN OUTCOMES AND MEASURES Patient PASI and adalimumab and ADA concentrations. RESULTS Antidrug antibody formed in 49% of patients, before week 24 in 90% of them. Adalimumab and ADA concentrations, clinical response and ADA concentration, and adalimumab concentration and clinical response had correlations of -0.872, -0.606, and 0.519, respectively. The adalimumab dose interval was shortened because of lack of efficacy in 15 patients, 7 with and 8 without ADA; improvement in responder status occurred in 1 of 7 and 4 of 8, respectively. CONCLUSIONS AND RELEVANCE Patients with no ADA formation in the first 24 weeks of treatment have little chance of it in the following 24 weeks. The presence of ADA is strongly correlated with adalimumab concentration and greatly influences clinical response. If ADA is present, dose interval shortening is less useful.
• JAMA dermatology.JAMA Dermatol.2013 Dec 18. doi: 10.1001/jamadermatol.2013.8347. [Epub ahead of print]
• IMPORTANCE In a previously reported cohort of 29 patients with plaque-type psoriasis followed up for 24 weeks, clinically relevant antidrug antibody (ADA) to adalimumab was frequently found. Long-term data were lacking. We now present the extension of this study: 80 patients followed up for 1 year.
• PMID 24352354

• Exchanging conformations of a hydroformylation catalyst structurally characterized using two-dimensional vibrational spectroscopy.

• Panman MR, Vos J, Bocokić V, Bellini R, de Bruin B, Reek JH, Woutersen S.Author information Van 't Hoff Institute for Molecular Sciences, University of Amsterdam , Science Park 904, 1098 XH Amsterdam, The Netherlands.AbstractCatalytic transition-metal complexes often occur in several conformations that exchange rapidly (<ms) in solution so that their spatial structures are difficult to characterize with conventional methods. Here, we determine specific bond angles in the two rapidly exchanging solution conformations of the hydroformylation catalyst (xantphos)Rh(CO)2H using two-dimensional vibrational spectroscopy, a method that can be applied to any catalyst provided that the exchange between its conformers occurs on a time scale of a few picoseconds or slower. We find that, in one of the conformations, the OC-Rh-CO angle deviates significantly from the canonical value in a trigonal-bipyramidal structure. On the basis of complementary density functional calculations, we ascribe this effect to attractive van der Waals interaction between the CO and the xantphos ligand.
• Inorganic chemistry.Inorg Chem.2013 Dec 16;52(24):14294-8. doi: 10.1021/ic402254q. Epub 2013 Nov 20.
• Catalytic transition-metal complexes often occur in several conformations that exchange rapidly (<ms) in solution so that their spatial structures are difficult to characterize with conventional methods. Here, we determine specific bond angles in the two rapidly exchanging solution conformations
• PMID 24256078

• New endeavors in gold catalysis-size matters.

• Gramage-Doria R, Reek JN.Author information Van't Hoff Institute for Molecular Sciences, University of Amsterdam, Science Park 904, 1098 XH, Amsterdam (The Netherlands) http://www.science.uva.nl/research/imc/HomKat/. r.gramagedoria@uva.nl.AbstractGolden times: Recent breakthroughs in gold-catalyzed transformations using nanosized homogeneous gold catalysts are highlighted. These catalysts have activities and stabilities comparable to (or even surpassing) heterogeneous catalysts. Well-defined, ligand-supported gold clusters turned out to be active in homogeneous catalysis, a catalyst concept which holds potential for future studies.
• Angewandte Chemie (International ed. in English).Angew Chem Int Ed Engl.2013 Dec 9;52(50):13146-8. doi: 10.1002/anie.201307205. Epub 2013 Oct 15.
• Golden times: Recent breakthroughs in gold-catalyzed transformations using nanosized homogeneous gold catalysts are highlighted. These catalysts have activities and stabilities comparable to (or even surpassing) heterogeneous catalysts. Well-defined, ligand-supported gold clusters turned out to be a
• PMID 24129977

Japanese Journal

• Urological complications of renal transplantation : a series of 900 cases

• REEK C.
• Transplant. Proc. 35, 2106-2107, 2003
• NAID 30010041098

• A wearable defibrillator for patients with an intermittent risk of arrhythmia

• REEK S
• Dtsch Med Wochenschr 127, 2127-2130, 2002
• NAID 30015475429

• <no title>

• REEK J. N. H.
• J. Am. Chem. Soc. 119, 9956-9964, 1997
• NAID 80009973938

Related Pictures

---

★リンクテーブル★

拡張検索

「creek」

「creek」

　　[★]

• クリーク、入り江